Worth reading
73In focus
Scored from 3 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-983
¥ million (operating profit for the quarter)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Financial Results PresentationFirst quarter of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥47,405 million-5.2%
Operating profit¥-983 million
Ordinary income¥-339 million
Net income¥-756 million
Gross Profit Margin53.7%
Selling, general and administrative expenses¥26,442 million
Results for the three months of the current quarterRevenue of ¥47.405 billion, operating loss of ¥983 million, ordinary loss of ¥339 million, and net loss attributable to owners of the parent of ¥756 million. All figures are standalone results for Q1.
Full-year earnings forecast
Net Sales
¥232,500 million
Operating profit
¥23,500 million
Ordinary income
¥23,500 million
Profit attributable to owners of the parent
¥15,000 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Initial forecast unchangedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in gross profit from growth in underlying revenue¥106 million
- Decrease in gross profit following the discontinuation of Abbott products¥-830 million
- Selling price and cost impact¥-1,245 million
- Increase in selling, general and administrative expenses¥-626 million
- Foreign exchange impact¥212 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Average exchange rate¥150 per US dollar and ¥175 per euro
Annual foreign exchange sensitivity
US dollars
Net Sales¥520 million
Operating profit¥180 million
Euro
Net Sales¥60 million
Operating profit¥20 million
New initiatives
- Expansion of the AlarmSense alarm solution in the US and Europe
- Launch of the QP-841N on-site alarm analysis software in Japan
- Launch in Japan of the QL-131W D-dimer license for the MEK-1303 Celltac α+ fully automated hematology analyzer and immunoassay system
- QP-842N software for supporting hospital admission and discharge operations
- Launch of the new CRM system and introduction of in-house-developed AI applications
Key KPIsA metric the company considers important as a management benchmark.
- Number of new facilities contracted for Alarm Report services (Japan)202 Facility
- Number of MD Linkage-connected devices (Japan and overseas)745 Units
- Number of facilities adopting DX (Japan)256 Facility
- Overseas revenue ratio45.0%Year on year against the same period last year+6.3 percentage points
Medium-term management plan targets
FY27/3 operating margin improvement target5-point improvement
FY27/3 target4.5-point improvement in operating margin
Financial targets
Equity ratio
End of fiscal year ending March 202670.1%
End of first quarter of fiscal year ending March 202772.0%
Capital expenditures
¥395 million Q1 actual
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥47,405 million (YoY -5.2%) |
| Operating profit | ¥-983 million |
| Ordinary income | ¥-339 million |
| Net income | ¥-756 million |
| Gross Profit Margin | 53.7% |
| Selling, general and administrative expenses | ¥26,442 million |
| Results for the three months of the current quarter | Revenue of ¥47.405 billion, operating loss of ¥983 million, ordinary loss of ¥339 million, and net loss attributable to owners of the parent of ¥756 million. All figures are standalone results for Q1. |
| Full-year earnings forecast | Net Sales ¥232,500 million / Operating profit ¥23,500 million / Ordinary income ¥23,500 million / Profit attributable to owners of the parent ¥15,000 million |
| Self-assessment against the plan | Initial forecast unchanged |
| Breakdown of Factors Affecting the Change | Factors Increase in gross profit from growth in underlying revenue / Amount ¥106 million, Factors Decrease in gross profit following the discontinuation of Abbott products / Amount ¥-830 million, Factors Selling price and cost impact / Amount ¥-1,245 million, Factors Increase in selling, general and administrative expenses / Amount ¥-626 million, Factors Foreign exchange impact / Amount ¥212 million |
| Key KPIs | Indicator name Number of new facilities contracted for Alarm Report services (Japan) / Value 202 Facility / Year on year against the same period last year Not disclosed, Indicator name Number of MD Linkage-connected devices (Japan and overseas) / Value 745 Units / Year on year against the same period last year Not disclosed, Indicator name Number of facilities adopting DX (Japan) / Value 256 Facility / Year on year against the same period last year Not disclosed, Indicator name Overseas revenue ratio / Value 45.0% / Year on year against the same period last year +6.3 percentage points |
| Assumptions Underlying the Business Outlook | Average exchange rate ¥150 per US dollar and ¥175 per euro / Annual foreign exchange sensitivity US dollars Net Sales ¥520 million / Operating profit ¥180 million / Euro Net Sales ¥60 million / Operating profit ¥20 million |
| Medium-term management plan targets | FY27/3 operating margin improvement target 5-point improvement / FY27/3 target 4.5-point improvement in operating margin |
| Financial targets | Equity ratio End of fiscal year ending March 2026 70.1% / End of first quarter of fiscal year ending March 2027 72.0% |
| Capital expenditures | ¥395 million (Q1 actual) |
| New initiatives | Expansion of the AlarmSense alarm solution in the US and Europe, Launch of the QP-841N on-site alarm analysis software in Japan, Launch in Japan of the QL-131W D-dimer license for the MEK-1303 Celltac α+ fully automated hematology analyzer and immunoassay system, QP-842N software for supporting hospital admission and discharge operations, Launch of the new CRM system and introduction of in-house-developed AI applications |
Items this document does not state (13)
Operating profit marginProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Domestic revenue declined due to lower sales of Abbott products and restrictions on purchases of locally sourced products. Operating results were affected by the decline in domestic revenue as well as higher SG&A expenses, including costs associated with wage increases.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.